New heart valve replacement could help thousands avoid Open-Heart surgery

NCT ID NCT07516444

First seen Jun 27, 2026 · Last updated Aug 17, 2026 · Updated 1 time

Summary

This study tests a new device called the VDyne System, which is placed inside the heart through a tube in a blood vessel to replace a leaky tricuspid valve. The trial will include 730 people with severe symptoms who have not improved with medication. Researchers will compare the VDyne device to another approved device to see which is safer and more effective at improving quality of life and reducing heart failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VDyne transcatheter tricuspid valve replacement system
What this could lead to
If successful, this could offer a less invasive treatment option for people with severe tricuspid regurgitation, potentially reducing symptoms and hospitalizations.
What could go wrong
This is an early pivotal trial, and the device may not work as well as expected or could cause serious complications like bleeding, stroke, or kidney injury. Long-term benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES (CVD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Minneapolis Heart Institute Foundation

    RECRUITING

    Minneapolis, Minnesota, 55407, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.